Actuate Therapeutics Inc (ACTU) Investor Relations Documents

Actuate Therapeutics Inc (ACTU) investor relations documents from the company's IR site: 10 press releases. Read in-app with summaries. First-party data.

Investor relations documents — source: company IR site

Published	Type	Document
2026-06-09	Press release	Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma
2026-06-01	Press release	Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elragl
2026-05-11	Press release	Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglu
2026-05-06	Press release	Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors
2026-04-14	Press release	Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Sur
2026-03-09	Press release	Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors
2026-02-24	Press release	Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
2026-01-21	Press release	Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical
2026-01-12	Press release	Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended
2026-01-06	Press release	Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric C

ACTU overview · ACTU earnings · ACTU financials · ACTU KPIs · ACTU ownership · ACTU peers · ACTU filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.